127. Frontotemporal lobar degeneration Clinical trials / Disease details
Clinical trials : 90 / Drugs : 87 - (DrugBank : 30) / Drug target genes : 39 - Drug target pathways : 88
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05742698 (ClinicalTrials.gov) | June 2023 | 23/11/2022 | Nabilone for Agitation in Frontotemporal Dementia | Double Blind Crossover Clinical Trial of Nabilone for Agitation in Frontotemporal Dementia | Frontotemporal Dementia;Frontotemporal Dementia, Behavioral Variant;Primary Progressive Aphasia | Drug: Nabilone;Drug: Placebo | Simon Ducharme, MD | Alzheimer's Drug Discovery Foundation | Not yet recruiting | 18 Years | N/A | All | 45 | Phase 3 | NULL |